Latest News
-
Monday - September 21, 2020
Initiative offers financial support for novel approaches and enabling technologies in crop research
Bayer opens application window for Grants4Ag » more
-
Thursday - September 17, 2020
ESMO Virtual Congress 2020:
New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors
78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integrated dataset with brain metastases (n=14), ORR was 71%, and 57% in patients with lung cancer with brain metastases (n=7) » more
-
Tuesday - September 15, 2020
Bayer Launches Large-scale Pre-launch Trial of New Tomato Varieties with Resistance to Tomato Brown Rugose Fruit Virus (ToBRFV)
The trials, which begin late September in Mexico, will target two varieties of Roma tomatoes which show little or no symptoms of ToBRFV / Developing these varieties aligns with Bayer’s commitment to provide fruit and vegetable seeds from its Seminis and De Ruiter brands which help growers combat the challenges they face each season » more
-
Tuesday - September 15, 2020
Not intended for U.S. and UK Media
Bayer and Systems Oncology sign exclusive license agreement on innovative breast cancer treatment approach ERSO™ » more
-
Thursday - September 10, 2020
Bayer: Supervisory Board extends CEO Werner Baumann’s contract until the end of April 2024
Company also announces progress in Roundup™ settlements » more
-
Wednesday - September 9, 2020
Not intended for U.S. and UK Media
New England Journal of Medicine publishes final overall survival data for Nubeqa™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancer
Men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003) / Darolutamide significantly improved all other secondary endpoints, including time to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE) / The safety profile at final analysis remains consistent with the earlier analysis; overall, the rate of adverse events was comparable to ADT alone » more
-
Wednesday - September 9, 2020
Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseases
Drug Discovery partnership and equity investment led by Leaps by Bayer in Series D financing round / Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster » more
-
Wednesday - September 9, 2020
Not intended for U.S. and UK Media
Bayer completes acquisition of UK-based biotech company KaNDy Therapeutics Ltd. » more
-
Tuesday - September 8, 2020
Not intended for U.S. and UK Media
Bayer to showcase new data from evolving Oncology portfolio at ESMO Virtual Congress 2020
Long-term efficacy and safety results for larotrectinib (Vitrakvi™) from an integrated data set of adult and pediatric patients with TRK fusion cancer, as well as sub-analyses in advanced thyroid and lung cancer patients / Tolerability and treatment response data from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Continued research to explore potential of marketed products, evaluating regorafenib (Stivarga™) and radium-223 dichloride (Xofigo™) in combination with immunotherapies » more
-
Friday - August 28, 2020
Not intended for U.S. and UK Media
Bayer submits vericiguat for marketing authorization in China for the treatment of chronic heart failure » more
-
Thursday - August 27, 2020
Bayer and Northpond Ventures lead USD 55 million Series A financing round for Triumvira Immunologics
Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments / Triumvira’s T-cell therapies have transformative potential as a new type of cancer treatment that uses the immune system to fight cancer / Pipeline includes four therapeutic candidates for both autologous and allogeneic T-cell immuno therapies for treatment of liquid and solid tumors » more
-
Thursday - August 27, 2020
Not intended for U.S. and UK Media
Bayer receives approval for Xofigo® in China » more
-
Monday - August 24, 2020
Bayer and Informed Data Systems Inc. (One Drop) join forces to jointly develop digital health products across therapeutic areas
Deal value up to USD 98 million including increased equity stake and joint development of digital health platform / Collaboration reinforces Bayer’s commitment to developing integrated care solutions for patients » more
-
Friday - August 21, 2020
More than 950 companies join in the fight against climate change
Science Based Targets initiative endorses climate protection targets of Bayer AG
Important step in Bayer becoming climate-neutral by 2030 / Targets integral to Board of Management remuneration » more
-
Thursday - August 20, 2020
Bayer announces resolution of U.S. Essure™ claims » more
-
Tuesday - August 18, 2020
Bayer Names Sara Boettiger as Head of Global Public Affairs, Science and Sustainability for Crop Science Division » more
-
Wednesday - August 12, 2020
Bayer and Temasek unveil innovative new company focused on developing breakthroughs in vertical farming
Initial efforts will focus on innovating vegetable varieties that deliver optimized quality and sensory experience / Called Unfold, the new company will be headquartered in the Davis, Calif., area with key operations in both the U.S. and Singapore / John Purcell appointed as CEO » more
-
Tuesday - August 11, 2020
Not intended for U.S. and UK Media
Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd.
Further expansion of Bayer’s drug development pipeline in Women’s Healthcare / Innovative non-hormonal oral compound NT-814 to alleviate menopausal symptoms / Development compound recently completed Phase IIb / Reinforces Bayer’s position in Women’s Healthcare / Upfront consideration of USD 425 million and additional potential consideration in the form of milestone payments » more
-
Thursday - August 6, 2020
Bayer stands by Kenya and Uganda in fight against desert locust devastation
Insecticide donation enables treatment of 170,000 hectares of the most affected fields » more
-
Tuesday - August 4, 2020
Second quarter of 2020:
Bayer: Solid performance despite COVID-19 impact
Ensuring employee safety and maintaining supply chains remain top priorities / Group sales decline by 2.5 percent (Fx & portfolio adj.) to 10.054 billion euros / EBITDA before special items up 5.6 percent to 2.883 billion euros / Crop Science reports operational growth / Sales and earnings at Pharmaceuticals down mainly due to volume-based procurement policy in China and COVID-19 / Sales at Consumer Health decline slightly (Fx & portfolio adj.) after strong demand in first quarter / Net loss of 9.548 billion euros due to special items for litigations – agreements in major legacy Monsanto litigation / Core earnings per share increase by 5.3 percent to 1.59 euros / Free cash flow rises to 1.402 billion euros / Outlook adjusted for COVID-19 impact » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Tuesday, November 3, 2020
Q3 2020 Quarterly Statement
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV